Autoinhibition of Bcr-Abl Through Its SH3 Domain

Overview

Journal Mol Cell

Publisher Cell Press

Specialty Cell Biology

Date 2003 Jul 31

PMID 12887890

Citations 59

Authors

Kristen M Smith

Rinat Yacobi

Richard A Van Etten

Affiliations

Soon will be listed here.

Abstract

Bcr-Abl is a dysregulated tyrosine kinase whose mechanism of activation is unclear. Here, we demonstrate that, like c-Abl, Bcr-Abl is negatively regulated through its SH3 domain. Kinase activity, transformation, and leukemogenesis by Bcr-Abl are greatly impaired by mutations of the Bcr coiled-coil domain that disrupt oligomerization, but restored by an SH3 point mutation that blocks ligand binding or a complementary mutation at the intramolecular SH3 binding site defined in c-Abl. Phosphorylation of tyrosines in the activation loop of the catalytic domain and the linker between the SH2 and catalytic domains (SH2-CD linker) is dependent on oligomerization and required for leukemogenesis. These results suggest that Bcr-Abl has a monomeric, unphosphorylated state with the SH3 domain engaged intramolecularly to Pro1124 in the SH2-CD linker, the form that is sensitive to the inhibitor imatinib (STI-571). The sole function of the coiled-coil domain is to disrupt the autoinhibited conformation through oligomerization and intermolecular autophosphorylation.

Citing Articles

Tyrosine kinases: multifaceted receptors at the intersection of several neurodegenerative disease-associated processes.

Stevenson M, Algarzae N, Moussa C Front Dement. 2024; 3:1458038.

PMID: 39221072 PMC: 11361951. DOI: 10.3389/frdem.2024.1458038.

A side-by-side comparison of variant function measurements using deep mutational scanning and base editing.

Sokirniy I, Inam H, Tomaszkiewicz M, Reynolds J, McCandlish D, Pritchard J bioRxiv. 2024; .

PMID: 39005366 PMC: 11244880. DOI: 10.1101/2024.06.30.601444.

Protein conformational ensembles in function: roles and mechanisms.

Nussinov R, Liu Y, Zhang W, Jang H RSC Chem Biol. 2023; 4(11):850-864.

PMID: 37920394 PMC: 10619138. DOI: 10.1039/d3cb00114h.

High Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability.

Massimino M, Stella S, Tirro E, Pennisi M, Stagno F, Vitale S Onco Targets Ther. 2023; 16:803-816.

PMID: 37807980 PMC: 10559794. DOI: 10.2147/OTT.S413825.

Domain Architecture of the Nonreceptor Tyrosine Kinase Ack1.

Kan Y, Paung Y, Seeliger M, Miller W Cells. 2023; 12(6).

PMID: 36980241 PMC: 10047419. DOI: 10.3390/cells12060900.

References

McWhirter J, Galasso D, Wang J . A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol. 1993; 13(12):7587-95. PMC: 364830. DOI: 10.1128/mcb.13.12.7587-7595.1993. View

Echarri A, Pendergast A . Activated c-Abl is degraded by the ubiquitin-dependent proteasome pathway. Curr Biol. 2001; 11(22):1759-65. DOI: 10.1016/s0960-9822(01)00538-3. View

Franz W, Berger P, Wang J . Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential. EMBO J. 1989; 8(1):137-47. PMC: 400782. DOI: 10.1002/j.1460-2075.1989.tb03358.x. View

Plattner R, Kadlec L, DeMali K, Kazlauskas A, Pendergast A . c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev. 1999; 13(18):2400-11. PMC: 317022. DOI: 10.1101/gad.13.18.2400. View

Dorey K, Engen J, Kretzschmar J, Wilm M, Neubauer G, Schindler T . Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase. Oncogene. 2002; 20(56):8075-84. DOI: 10.1038/sj.onc.1205017. View

Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, Kuriyan J . A myristoyl/phosphotyrosine switch regulates c-Abl. Cell. 2003; 112(6):845-57. DOI: 10.1016/s0092-8674(03)00191-0. View

Brasher B, Van Etten R . c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J Biol Chem. 2000; 275(45):35631-7. DOI: 10.1074/jbc.M005401200. View

Wen S, Van Etten R . The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev. 1997; 11(19):2456-67. PMC: 316562. DOI: 10.1101/gad.11.19.2456. View

Plattner R, Irvin B, Guo S, Blackburn K, Kazlauskas A, Abraham R . A new link between the c-Abl tyrosine kinase and phosphoinositide signalling through PLC-gamma1. Nat Cell Biol. 2003; 5(4):309-19. DOI: 10.1038/ncb949. View

10.

Barila D, Superti-Furga G . An intramolecular SH3-domain interaction regulates c-Abl activity. Nat Genet. 1998; 18(3):280-2. DOI: 10.1038/ng0398-280. View

11.

Sicheri F, Moarefi I, Kuriyan J . Crystal structure of the Src family tyrosine kinase Hck. Nature. 1997; 385(6617):602-9. DOI: 10.1038/385602a0. View

12.

Zhang X, Subrahmanyam R, Wong R, Gross A, Ren R . The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl. Mol Cell Biol. 2001; 21(3):840-53. PMC: 86675. DOI: 10.1128/MCB.21.3.840-853.2001. View

13.

Nagar B, Hantschel O, Young M, Scheffzek K, Veach D, Bornmann W . Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell. 2003; 112(6):859-71. DOI: 10.1016/s0092-8674(03)00194-6. View

14.

Schindler T, Bornmann W, Pellicena P, Miller W, Clarkson B, Kuriyan J . Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000; 289(5486):1938-42. DOI: 10.1126/science.289.5486.1938. View

15.

Roumiantsev S, Shah N, Gorre M, Nicoll J, Brasher B, Sawyers C . Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A. 2002; 99(16):10700-5. PMC: 125018. DOI: 10.1073/pnas.162140299. View

16.

Pendergast A, Gishizky M, Havlik M, Witte O . SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence. Mol Cell Biol. 1993; 13(3):1728-36. PMC: 359485. DOI: 10.1128/mcb.13.3.1728-1736.1993. View

17.

McLaughlin J, Chianese E, Witte O . In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci U S A. 1987; 84(18):6558-62. PMC: 299118. DOI: 10.1073/pnas.84.18.6558. View

18.

He Y, Wertheim J, Xu L, Miller J, Karnell F, Choi J . The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood. 2002; 99(8):2957-68. DOI: 10.1182/blood.v99.8.2957. View

19.

Azam M, Latek R, Daley G . Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 2003; 112(6):831-43. DOI: 10.1016/s0092-8674(03)00190-9. View

20.

Pluk H, Dorey K, Superti-Furga G . Autoinhibition of c-Abl. Cell. 2002; 108(2):247-59. DOI: 10.1016/s0092-8674(02)00623-2. View